Premium
RE‐MI‐DO Study: resultats of a multicenter study of dexamethasone implantation in eyes with macular oedema in retinal vein occlusion
Author(s) -
POMMIER S,
MEYER F
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.s042.x
Subject(s) - medicine , macular edema , central retinal vein occlusion , retinal vein , dexamethasone , ophthalmology , visual acuity , intraocular pressure , occlusion , retrospective cohort study , retinal , branch retinal vein occlusion , surgery
Purpose Retrospective Multicentric Study of the dexamethasone drug delivery system (OZURDEX) in the treatment of macular edema following retinal vein occlusion To evaluate the safety and efficacy of the dexamethasone drug delivery system (OZURDEX) in eyes with macular edema following branch (BRVO) or central retinal vein occlusion (CRVO). Methods Retrospective, noncomparative, multicentric Study with a minimum of 6 months follow‐up 220 patients with retinal vein occlusion (55.9% BRVO, 44.1% CRVO) have been included in the study with a minimum follow‐up of 6 months (mean follow‐up = 10.2 months). The patients received one or more OZURDEX in the study eye during the follow‐up. 8 French ophthalmic centers have participated to the study. Best‐corrected visual acuity (BCVA), central retinal thickness (CRT) intraocular pressure (IOP) variation and cataract progression were evaluated monthly from baseline to 6 months. Results The initial CRT was 657.2 microns and decrease by 49.8% at M1, 55.2% at M3 and 28.1% at M6. The initial BCVA was 48 letters. AV> 20/40 was observed in 41% of patients at M1, 47.8% at M3 and 19.9% at M6. 50.8% of patients at M1, 55.9% at M3, and 35.1% at M6 had an improvement ≥ 15‐letters in BCVA from baseline. An IOP > 25mmHg was observed in 15.8% of patients. 6% of had an increase ≥ 10‐mmHg from baseline during the first month after the first injection. These IOP increase were transients At 6 months, one third of the patients required a second injection. The mean time for reinjection was 5,3 months. Conclusion Ozurdex provides an efficient and risk‐benefit ratio acceptable to the treatment of RVO patients with macular edema.